Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

ONCOLOGY® Looks to Conference Agendas for Current Trends

November 10, 2021
By Mike Hennessy Sr, Founder and Chairman, MJH Life Sciences
Publication
Article
OncologyONCOLOGY Vol 35, Issue 11
Volume 35
Issue 11
Pages: 703

"Witnessing the resiliency of the oncology community in the face of challenges to both patients and their providers builds momentum in the community and is sure to lead to better outcomes going forward."

As we approach the last few weeks of 2021, the oncology community is abuzz with news about major medical conferences and research breakthroughs presented therein. What’s also evident when looking at conference agendas is just how much has changed in the treatment of cancer, with presentations dominated by topics related to extending health care to underserved populations and managing care with consideration to the COVID-19 pandemic.

Scheduled for presentation at the Society for Immunotherapy of Cancer’s 36th Annual Meeting, taking place from November 10 through 14, are sessions covering topics related to COVID-19’s impact on immunology and immunobiology and what the pandemic means to the conduct of clinical trials. Leaders in the field, such as Jeffrey Weber, MD, PhD, of NYU Langone Medical Center, will provide their expertise in this area.

At the upcoming American Society for Hematology Annual Meeting and Exposition, awards will include honoring Deepika Darbari, MD, of Children’s National Hospital and the George Washington University School of Medicine and Health Sciences, for her lifetime of work to both advance minority representation professionally and strive for better care for underrepresented patient populations.

At the San Antonio Breast Cancer Symposium taking place in December, a special session titled “Trust in Science and Healthcare” will explore how investigators can extend the reach of patient care the underserved populations with key thought leaders, such as Eric P. Winer, MD, of Dana-Farber Cancer Institute, taking the helm for certain parts of the discussion.

Witnessing the resiliency of the oncology community in the face of challenges to both patients and their providers builds momentum in the community and is sure to lead to better outcomes going forward. As always, oncology providers across multidisciplinary specialties can stay up-to-date on the latest in this and other oncology news at CancerNetwork.com, home of the journal ONCOLOGY®.

Download Issue PDF
Articles in this issue

Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials
Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials
Abstracts From the 18th Annual Meeting of the International Society of Gastrointestinal Oncology
Abstracts From the 18th Annual Meeting of the International Society of Gastrointestinal Oncology
Treatment of Locally Advanced Cervical Cancer With Kidney Failure and Comorbidities
Treatment of Locally Advanced Cervical Cancer With Kidney Failure and Comorbidities
A Rare Case of Glioblastoma With Extensive Liver Metastases
A Rare Case of Glioblastoma With Extensive Liver Metastases
Expert Commentary on the Product Profile of Tepotinib
Expert Commentary on the Product Profile of Tepotinib
How the Study of Leukemias Inspired a Decades-Long Career
How the Study of Leukemias Inspired a Decades-Long Career
LEADing the Way: Leadership,  Empowerment, and Development Conference
LEADing the Way: Leadership, Empowerment, and Development Conference
ONCOLOGY® Looks to Conference Agendas for Current Trends
ONCOLOGY® Looks to Conference Agendas for Current Trends
Recent Videos
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content
Advertisement

Osimertinib/Chemo Yields OS Improvement Across Subgroups of EGFR+ NSCLC

Osimertinib/Chemo Yields OS Improvement Across Subgroups of EGFR+ NSCLC

Chris Ryan
October 17th 2025
Article

Osimertinib plus chemotherapy significantly improved overall survival in EGFR-mutated NSCLC, outperforming monotherapy across various prognostic factors.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Osimertinib and local consolidative therapy was a safe and effective strategy to extend disease control in patients with advanced EGFR-mutant NSCLC.

Local Consolidative Therapy Plus Osimertinib Yields PFS Benefit in Metastatic EGFR-Mutant NSCLC

Kristi Rosa
October 17th 2025
Article

Osimertinib and local consolidative therapy was a safe and effective strategy to extend disease control in patients with advanced EGFR-mutant NSCLC.


Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.


Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer

Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer

Kyle Doherty
October 17th 2025
Article

Adjuvant ribociclib plus aromatase inhibitors significantly improved invasive disease-free survival in early breast cancer, as shown in the NATALEE trial.


Data from monarchE showed an OS benefit with abemaciclib-based therapy that was consistent across prespecified patient subgroups.

Abemaciclib Regimen Improves Survival in HR+/HER2– Early Breast Cancer

Ashling Wahner
October 17th 2025
Article

Data from monarchE showed an OS benefit with abemaciclib-based therapy that was consistent across prespecified patient subgroups.

Related Content
Advertisement

Osimertinib/Chemo Yields OS Improvement Across Subgroups of EGFR+ NSCLC

Osimertinib/Chemo Yields OS Improvement Across Subgroups of EGFR+ NSCLC

Chris Ryan
October 17th 2025
Article

Osimertinib plus chemotherapy significantly improved overall survival in EGFR-mutated NSCLC, outperforming monotherapy across various prognostic factors.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Osimertinib and local consolidative therapy was a safe and effective strategy to extend disease control in patients with advanced EGFR-mutant NSCLC.

Local Consolidative Therapy Plus Osimertinib Yields PFS Benefit in Metastatic EGFR-Mutant NSCLC

Kristi Rosa
October 17th 2025
Article

Osimertinib and local consolidative therapy was a safe and effective strategy to extend disease control in patients with advanced EGFR-mutant NSCLC.


Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.


Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer

Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer

Kyle Doherty
October 17th 2025
Article

Adjuvant ribociclib plus aromatase inhibitors significantly improved invasive disease-free survival in early breast cancer, as shown in the NATALEE trial.


Data from monarchE showed an OS benefit with abemaciclib-based therapy that was consistent across prespecified patient subgroups.

Abemaciclib Regimen Improves Survival in HR+/HER2– Early Breast Cancer

Ashling Wahner
October 17th 2025
Article

Data from monarchE showed an OS benefit with abemaciclib-based therapy that was consistent across prespecified patient subgroups.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.